Sector landing page

Pharma valuations

pharma-franchise cohort (Indian domestic-OTC + branded chronic-care MNCs). Terminal growth lifts to 5.5% to reflect India healthcare nominal-spend tailwind and pricing-power durability. CDMO names (DIVISLAB, SYNGENE) use a separate 4.5% lift under the same framework. Hospital chains are tracked under a sibling cohort (MAXHEALTH, FORTIS, APOLLOHOSP, etc.) at 5.5%.

Tickers

Median MoS

-24.3%

Median score

Median ROE

15.6%

Verdict distribution

Undervalued1Fairly valued5Overvalued5

Cohort constituents

	Name			FV	Price
ABBOTINDIA	Abbott India Limited	58	-16.1	21897.19	26105.00	Fairly valued
GLAXO	GlaxoSmithKline Pharmaceuticals Limited	58	-13.6	1896.20	2194.70	Fairly valued
DRREDDY	Dr. Reddy's Laboratories Limited	55	19.7	1518.61	1268.50	Fairly valued
SUNPHARMA	Sun Pharmaceutical Industries	53	-24.3	1346.48	1779.00	Fairly valued
ERIS	Eris Lifesciences Limited	50	-46.4	735.63	1373.70	data_limited
CIPLA	Cipla Limited	45	-11.5	1218.32	1376.50	Fairly valued
PFIZER	Pfizer Limited	43	-18.9	3725.27	4592.50	avoid
MANKIND	Mankind Pharma Limited	40	-56.0	1051.43	2391.00	Overvalued
TORNTPHARM	Torrent Pharmaceuticals Limited	40	-64.1	1605.17	4472.90	Overvalued
DIVISLAB	Divi's Laboratories Limited	40	-63.3	2481.45	6753.00	Overvalued
GLAND	Gland Pharma Limited	40	-37.3	1435.13	2288.50	Overvalued
SANOFI	SANOFI INDIA LIMITED	40	73.8	5476.40	3151.80	Undervalued
AJANTPHARM	Ajanta Pharma Limited	32	-57.7	1276.33	3017.20	Overvalued